2025 Q4 -tulosraportti
4 päivää sittenTarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 16 335 | - | - | ||
| 1 500 | - | - | ||
| 980 | - | - | ||
| 44 588 | - | - |
Ylin
0,628VWAP
Alin
0,6VaihtoMäärä
0,4 626 115
VWAP
Ylin
0,628Alin
0,6VaihtoMäärä
0,4 626 115
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 20.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
- ·24.2.It's wild enough that you can buy ALZ over 10% lower than the subscription price of 0.8. They now have cash in hand - Fast Track, and if their Phase II turns out well, both Eli Lilly and Novo and others will be queuing up to acquire them... Specific precision at the core of the disease The vaccine candidate ALZ-101 is based on a scientific strategy that differs significantly from competitors. While players like BioArctic/Eisai/Biogen (lecanemab) and Eli Lilly (donanemab) focus on removing visible plaques or mixed forms of amyloid-beta, Alzinova specifically targets toxic oligomers. Research shows that these soluble protein clumps are the driving factor that kills brain synapses. Alzinova's Phase Ib study confirmed that the vaccine succeeded in generating high levels of antibodies that neutralized these specific oligomers without binding to plaque. Safety that stands out from competitors The difference in targets has direct consequences for the safety profile of the treatments. Plaque-binding treatments have historically struggled with side effects such as brain swelling (ARIA-E). However, no serious side effects were observed in Alzinova's Phase Ib study. The incidence of microhemorrhages (ARIA-H) was comparable to placebo, and the observed cases of ARIA-E were asymptomatic. This favorable safety profile was likely a contributing factor to the US FDA granting the candidate Fast Track designation in October 2025. link: https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
- 16.2.16.2.Alzinova's management on the rights issue, partnership dialogues and the path towards phase II https://www.biostock.se/en/2026/02/alzinovas-ledning-om-emission-partnerskapsdialoger-och-vagen-mot-fas-ii/
- 16.2.16.2.Alzinova raises 50 MSEK – targets partnership agreement in 2026 https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
4 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all
- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
- ·24.2.It's wild enough that you can buy ALZ over 10% lower than the subscription price of 0.8. They now have cash in hand - Fast Track, and if their Phase II turns out well, both Eli Lilly and Novo and others will be queuing up to acquire them... Specific precision at the core of the disease The vaccine candidate ALZ-101 is based on a scientific strategy that differs significantly from competitors. While players like BioArctic/Eisai/Biogen (lecanemab) and Eli Lilly (donanemab) focus on removing visible plaques or mixed forms of amyloid-beta, Alzinova specifically targets toxic oligomers. Research shows that these soluble protein clumps are the driving factor that kills brain synapses. Alzinova's Phase Ib study confirmed that the vaccine succeeded in generating high levels of antibodies that neutralized these specific oligomers without binding to plaque. Safety that stands out from competitors The difference in targets has direct consequences for the safety profile of the treatments. Plaque-binding treatments have historically struggled with side effects such as brain swelling (ARIA-E). However, no serious side effects were observed in Alzinova's Phase Ib study. The incidence of microhemorrhages (ARIA-H) was comparable to placebo, and the observed cases of ARIA-E were asymptomatic. This favorable safety profile was likely a contributing factor to the US FDA granting the candidate Fast Track designation in October 2025. link: https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
- 16.2.16.2.Alzinova's management on the rights issue, partnership dialogues and the path towards phase II https://www.biostock.se/en/2026/02/alzinovas-ledning-om-emission-partnerskapsdialoger-och-vagen-mot-fas-ii/
- 16.2.16.2.Alzinova raises 50 MSEK – targets partnership agreement in 2026 https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 16 335 | - | - | ||
| 1 500 | - | - | ||
| 980 | - | - | ||
| 44 588 | - | - |
Ylin
0,628VWAP
Alin
0,6VaihtoMäärä
0,4 626 115
VWAP
Ylin
0,628Alin
0,6VaihtoMäärä
0,4 626 115
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 20.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
4 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 20.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·25.2.Alzinova AB - Beyond plaques: the scientific rationale behind ALZ-101 Equity analyst Maria Karlsson Osipova interviews Alzinova's CSO and co-founder Anders Sandberg about ALZ-101 and the scientific basis for Alzinova's vaccine strategy against Alzheimer's disease. https://www.linkedin.com/company/dnbcarnegieaccess/posts/?feedView=all
- ·24.2.If you ask ChatGPT whether Novo or Eli Lilly could be interested in ALZ, you get this answer: Here are the results for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? Search instead for Could one imagine Eli Lilly or Novo Nordisk being interested in Alzinov AB? AI Overview Yes, it is theoretically possible that large pharmaceutical companies like Eli Lilly or Novo Nordisk could find Alzinova AB interesting, primarily due to their specialization in Alzheimer's treatment. Alzinova develops promising, disease-modifying treatments that specifically target the toxic amyloid-beta oligomers, which are believed to be the cause of Alzheimer's disease. www.inderes.se www.inderes.se Here is an analysis of why Alzinova AB may be of interest: Alzinova AB's pipeline (Why they are interesting): ALZ-101 (Vaccine): Alzinova's leading candidate is a therapeutic vaccine that has shown good results in Phase 1b trials. It has good tolerability, an acceptable safety profile, and a high immune response rate. AβCC-peptide technology: The company uses a patented technology that precisely targets the harmful oligomers (small protein clumps), which can offer an advantage over previous antibody treatments that target both healthy and diseased proteins. Upcoming Phase 2 studies: Alzinova has received approval to start Phase 2 studies, including in the USA, which is a critical milestone that increases attractiveness for larger partners. National Institutes of Health (.gov) National Institutes of Health (.gov) +4 Interest from Eli Lilly: Eli Lilly is already a leading player in Alzheimer's treatment with donanemab (Kisunla). Since Alzinova focuses on "oligomer-specific" treatments, which are considered rare, ALZ-101 (the vaccine) could be a strategic supplement to Lilly's current antibody pipeline. Alzinova Alzinova +1 Interest from Novo Nordisk: Novo Nordisk has a strong interest in neurodegenerative diseases, including Alzheimer's, and has previously investigated the potential of semaglutide (although their EVOKE trial did not show the expected effect in delaying disease progression). As Novo Nordisk is actively looking for new projects and acquisitions (focus on "other projects and acquisitions" per Feb 2026), a specialized player like Alzinova could be interesting to diversify their portfolio. Overall assessment: It is a widespread practice for large pharmaceutical companies to acquire smaller biotech companies (like the Swedish Alzinova) when their candidates have shown positive "proof-of-concept" in Phase 1 and are moving into Phase 2, as this reduces risk. Alzinova's niche technology against oligomers makes them an attractive partner or acquisition candidate for a player who wants to be a leader in next-generation Alzheimer's treatment.·24.2.And then they get help from one of the gurus in Alzheimer's. - Henrik Zetterberg... https://biostock.se/en/2026/02/henrik-zetterberg-om-ny-era-inom-alzheimersbehandling/
- ·24.2.It's wild enough that you can buy ALZ over 10% lower than the subscription price of 0.8. They now have cash in hand - Fast Track, and if their Phase II turns out well, both Eli Lilly and Novo and others will be queuing up to acquire them... Specific precision at the core of the disease The vaccine candidate ALZ-101 is based on a scientific strategy that differs significantly from competitors. While players like BioArctic/Eisai/Biogen (lecanemab) and Eli Lilly (donanemab) focus on removing visible plaques or mixed forms of amyloid-beta, Alzinova specifically targets toxic oligomers. Research shows that these soluble protein clumps are the driving factor that kills brain synapses. Alzinova's Phase Ib study confirmed that the vaccine succeeded in generating high levels of antibodies that neutralized these specific oligomers without binding to plaque. Safety that stands out from competitors The difference in targets has direct consequences for the safety profile of the treatments. Plaque-binding treatments have historically struggled with side effects such as brain swelling (ARIA-E). However, no serious side effects were observed in Alzinova's Phase Ib study. The incidence of microhemorrhages (ARIA-H) was comparable to placebo, and the observed cases of ARIA-E were asymptomatic. This favorable safety profile was likely a contributing factor to the US FDA granting the candidate Fast Track designation in October 2025. link: https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
- 16.2.16.2.Alzinova's management on the rights issue, partnership dialogues and the path towards phase II https://www.biostock.se/en/2026/02/alzinovas-ledning-om-emission-partnerskapsdialoger-och-vagen-mot-fas-ii/
- 16.2.16.2.Alzinova raises 50 MSEK – targets partnership agreement in 2026 https://www.biostock.se/en/2026/02/alzinova-tar-in-50-mkr-siktar-pa-partneravtal-2026/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 16 335 | - | - | ||
| 1 500 | - | - | ||
| 980 | - | - | ||
| 44 588 | - | - |
Ylin
0,628VWAP
Alin
0,6VaihtoMäärä
0,4 626 115
VWAP
Ylin
0,628Alin
0,6VaihtoMäärä
0,4 626 115
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 626 115 | 626 115 | 0 | 0 |